Alpine Immune Sciences, Inc.
GPTKB entity
Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2024
|
| gptkbp:focus |
gptkb:cancer
immunotherapy autoimmune diseases |
| gptkbp:founded |
2015
|
| gptkbp:founder |
gptkb:Mitchell_H._Gold
|
| gptkbp:hasCompany |
yes
|
| gptkbp:headquarters_location |
gptkb:Seattle,_Washington,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Alpine Immune Sciences, Inc.
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:ALPN-101
gptkb:ALPN-202 |
| gptkbp:numberOfEmployees |
approximately 100 (as of 2023)
|
| gptkbp:researchArea |
protein engineering
immune system modulation |
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ALPN
|
| gptkbp:website |
https://www.alpineimmunesciences.com/
|
| gptkbp:bfsParent |
gptkb:ALPMY
|
| gptkbp:bfsLayer |
6
|